What is Catalent?
Catalent operates as a critical Contract Development and Manufacturing Organization (CDMO), serving as the backbone for pharmaceutical, biotech, and consumer health innovators. By providing end-to-end solutions that span from early-stage product development to full-scale commercial manufacturing, the company enables its partners to accelerate time-to-market for personalized medicines and blockbuster therapeutics. Its deep-scale expertise in delivery technologies and supply chain management positions it as an indispensable partner in the life sciences sector, ensuring that essential treatments reach patients with precision and efficiency.
How much funding has Catalent raised?
Catalent has raised a total of $5.2B across 9 funding rounds:
Stock Offering
$870M
Debt
$410.1M
Stock Offering
$24.2M
Debt
$450M
Stock Offering
$387M
Debt
$1.2B
Debt
$500M
Stock Offering
$500M
Debt
$903.4M
Stock Issuance/Offering (2014): $870M with participation from Undisclosed
Debt (2016): $410.1M led by Undisclosed
Stock Issuance/Offering (2017): $24.2M supported by RBC Capital Markets, JPMorgan Chase, BofA Merrill Lynch, and Morgan Stanley
Debt (2017): $450M featuring Undisclosed
Stock Issuance/Offering (2018): $387M backed by Wells Fargo Securities, JPMorgan Chase, RBC Capital Markets, BofA Merrill Lynch, and Morgan Stanley
Debt (2019): $1.2B with participation from JPMorgan Chase Bank
Debt (2019): $500M led by Undisclosed
Stock Issuance/Offering (2020): $500M supported by UBS Investment Bank and JPMorgan Chase
Debt (2020): $903.4M featuring Undisclosed
Key Investors in Catalent
JPMorgan Chase
A leading global financial services firm providing comprehensive investment banking and asset management solutions to institutional and corporate clients worldwide.
Morgan Stanley
A premier global financial services institution specializing in investment banking, securities, and wealth management for a diverse range of international clients.
BofA Merrill Lynch
A global financial services leader offering a broad spectrum of banking, lending, and risk management solutions to support large-scale corporate and institutional economic activity.
What's next for Catalent?
Looking ahead, Catalent is poised to leverage its significant capital reserves to further integrate advanced manufacturing technologies and expand its global reach. As the demand for complex biologics and specialized drug delivery systems continues to rise, the company's strategic focus will likely remain on enhancing its multi-modality manufacturing infrastructure. By maintaining a disciplined approach to capital allocation, Catalent is well-positioned to sustain its growth trajectory, drive operational excellence, and continue its role as a foundational pillar in the global pharmaceutical ecosystem.
See full Catalent company page
